Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

NCT01938001 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

358

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG: Rituximab
DRUG: Lenalidomide
DRUG: Placebo

Sponsor

Celgene